Listing Price: Fair Market Value
Opportunity Snapshot
• U.S.-based medtech platform redefining airway access with a novel nasal, supraglottic system that secures the airway in seconds without crossing the vocal cords or requiring paralytics.
• Patent-backed platform architecture covering balloon-based distal airway systems with integrated luminal channels—extending beyond a single device into a broad airway control category.
• Class I, 510(k)-exempt with a clear and accelerated commercialization pathway.
• Functional prototypes, finalized design parameters, and manufacturing pathway actively advancing toward scalable production.
Platform-Level IP Position
• Core utility patent favorably reviewed by USPTO, covering the fundamental architecture of a balloon-based airway tube with integrated luminal channels.
• Protection is structural and system-level, not limited to a single embodiment—creating defensible platform ownership across multiple airway applications.
• Establishes a barrier to entry against design-around attempts in nasal and alternative airway systems utilizing similar balloon-seal constructs.
• Provides freedom to operate + future pipeline protection, enabling expansion into adjacent indications (EMS, surgical, critical care, drug delivery).
• Represents category control, not product protection—a critical distinction for strategic acquirers.
Market Opportunity
• ~$2.5B U.S. nasal airway/intubation market growing to ~$4.1B (7%+ CAGR).
• >$7B global airway management market with increasing demand for non-invasive, rapid-access solutions.
• Expanding use cases across oral surgery, ambulatory care, EMS, military, and outpatient sedation—large, underpenetrated segments lacking optimal solutions.
• Strong tailwinds: shift to outpatient procedures, cost containment, and reduction of anesthesia complexity.
Technology Highlights
• Rapid airway access (seconds vs. minutes) without need for paralytics or advanced airway manipulation.
• Atraumatic supraglottic seal enabling positive-pressure ventilation without tracheal invasion.
• Tri-lumen architecture supporting suction + direct pharmacologic delivery (critical in emergent settings).
• Designed for ease of use across providers (not limited to highly specialized anesthesiologists).
Competitive Positioning
• Directly addresses core limitations of:
•LMA: inadequate seal, aspiration risk, poor high-pressure performance
•Endotracheal tubes: complexity, time, need for paralytics
•Tracheostomy: invasive, high complication burden
• Positioned as a new standard of care for short-duration airway control and emergent access.
• Potential to shift procedures out of higher-cost care settings (ICU/OR → outpatient/field).
Strategic Rationale for Acquirers
• Immediate portfolio expansion into a differentiated airway category with minimal regulatory friction.
• Ability to leverage existing distribution channels across anesthesia, EMS, and surgical markets.
• Platform enables follow-on SKUs and adjacent product lines under the same IP umbrella.
• Attractive for strategics seeking:
•Faster-to-market innovation vs. internal R&D
•Differentiated clinical outcomes
•High-margin disposable product lines
Investment Highlights
• Platform asset with defensible IP moat (not a single-product risk profile)
• De-risked regulatory pathway (Class I, 510(k)-exempt)
• Manufacturing pathway actively underway with clear line of sight to scale
• High-margin disposable model (>70% projected gross margins)
• Multiple exit pathways: full acquisition, licensing, or category roll-up
Transaction
• Company is pursuing a strategic transaction (acquisition or licensing) with valuation expectations aligned to a platform-level medtech asset.
• Structured process with active engagement from multiple counterparties.
• Comprehensive data room available, including:
•Prototype validation
•Engineering and manufacturing roadmap
•IP filings and legal opinions
Priority will be given to parties capable of executing against both commercialization and platform expansion.
Fill out our business inquiry form and we’ll reach out to discuss your details.
Dan Wilson comes to Viking with an extensive background in entrepreneurship and IT service and support as the previous owner and founder of Waypoint Solutions Group (rebranded and merged as Complete Network in 2017), a managed IT services provider located in North Carolina. Dan’s company held multiple awards as a five-time INC 5000 winner, an eight-time MSP501 winner (top MSP’s globally), as well as a three-time Charlotte Business Journal Fast 50 winner as one of the fastest growing companies in the Charlotte, NC area. Throughout his 16 years of entrepreneurship, Dan has experienced the facilitation and process of multiple merger and acquisition deals. His knowledge as a previous business owner gives him hands-on, firsthand experience in assisting other entrepreneurs in planning their exit strategies. Dan has seen the struggles and pitfalls surrounding the sale of a business, and he plans to make it his mission to guide and protect entrepreneurs in completing the single largest transaction of their lives.
Married for 17 years, Dan and his wife, Lynne, are the parents of three daughters. His hobbies outside of the office include sailing and cycling. From 1987-1998, Dan was a United States Air Force Active Duty, and is on the Board of Trustees for the Patriot Military Family Foundation, as well as a Board Member of the Adaptive Sports and Adventure Program (ASAP). He has also been a member of the Entrepreneurs Organization for 10 years, serving four years on the US East Regional Board, Local Chapter Board for eight years, and as President for two years. Dan hopes to bring professional and confidential representation to a segment of the Raleigh, NC market where it is hard to come by.
